دورية أكاديمية
Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
| العنوان: | Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers? |
|---|---|
| المؤلفون: | Akin C; Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich., Siebenhaar F; Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany., Wechsler JB; Division of Gastroenterology, Hepatology, and Nutrition, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill., Youngblood BA; Research & Preclinical Development, Allakos, Inc., San Carlos, Calif., Maurer M; Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. Electronic address: marcus.maurer@charite.de. |
| المصدر: | The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Jul; Vol. 12 (7), pp. 1727-1737. Date of Electronic Publication: 2024 Mar 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier Inc., [2013]- |
| مواضيع طبية MeSH: | Mast Cells*/immunology , Biomarkers*, Humans ; Tryptases/blood ; Cell Count ; Mastocytosis/diagnosis ; Animals |
| مستخلص: | The pathophysiology of mast cell (MC)-driven disorders is diverse, ranging from localized reactions to systemic disorders caused by abnormal accumulation and activation in multiorgan systems. Prompt and accurate diagnosis is critically important, both for informing treatment and objective assessment of treatment outcomes. As new therapeutics are being developed to deplete MCs or silence them (eg, by engaging inhibitory receptors that block activation), new biomarkers are needed that can distinguish between MC activation versus burden. Serum tryptase is the gold standard for assessing both MC burden and activation; however, commercial tryptase assays have limitations related to timing of release, lack of discernment between inactive (α) and active (β) forms of tryptase, and interpatient variability of baseline levels. Alternative approaches to measuring MC activation include urinary MC mediators, flow cytometry-based assays or gene expression profiling. Additional markers of MC activation are needed for use in clinical diagnostics, to help selection of treatment of MC diseases, and for assessing outcomes of therapy. We review the spectrum of disorders with known or suspected MC contribution, describe the utility and limitations of current MC markers and assays, and discuss the need for new markers that can differentiate between MC activation and burden. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Allergy; Assay; Biomarker; Marker; Mast cell; Tryptase; Urticaria |
| المشرفين على المادة: | 0 (Biomarkers) EC 3.4.21.59 (Tryptases) |
| تواريخ الأحداث: | Date Created: 20240311 Date Completed: 20240707 Latest Revision: 20240707 |
| رمز التحديث: | 20240708 |
| DOI: | 10.1016/j.jaip.2024.03.010 |
| PMID: | 38467332 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2213-2201 |
|---|---|
| DOI: | 10.1016/j.jaip.2024.03.010 |